Targeting Hypoxia-Inducible Factors for Antiangiogenic Cancer Therapy.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Trends in Cancer

• Publication date

  2017-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.trecan.2017.05.002PMID 28718406
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical Pharmacokinetics and Pharmacodynamics of Cabozantinib

  2017cited by this paper
• Hypoxia and cellular metabolism in tumour pathophysiology

  2017cited by this paper
• Understanding the Intersections between Metabolism and Cancer Biology.

  2017cited by this paper
• Molecular targeting of hypoxia in radiotherapy☆

  2017cited by this paper
• Antiangiogenic therapy in oncology: current status and future directions.

  2016cited by this paper
• Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma

  2016cited by this paper
• Targeting HIF2 in Clear Cell Renal Cell Carcinoma.

  2016cited by this paper
• HIF inhibitors for ischemic retinopathies and cancers: options beyond anti-VEGF therapies

  2016cited by this paper
• Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases

  2016cited by this paper
• Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V.

  2016cited by this paper
• On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models

  2016cited by this paper
• Targeting renal cell carcinoma with a HIF-2 antagonist

  2016cited by this paper
• The role of fatty acid β-oxidation in lymphangiogenesis

  2016cited by this paper
• The hypoxia-related signaling pathways of vasculogenic mimicry in tumor treatment.

  2016cited by this paper
• mTOR Signaling Confers Resistance to Targeted Cancer Drugs.

  2016cited by this paper
• Hypoxia-Inducible Factors: Master Regulators of Cancer Progression.

  2016cited by this paper
• Novel ABCG2 Antagonists Reverse Topotecan-Mediated Chemotherapeutic Resistance in Ovarian Carcinoma Xenografts

  2016cited by this paper
• Ten years of anti-vascular endothelial growth factor therapy

  2016cited by this paper
• The impact of hypoxia on tumor-associated macrophages.

  2016cited by this paper
• Hypoxia regulates ABCG2 activity through the activivation of ERK1/2/HIF-1α and contributes to chemoresistance in pancreatic cancer cells

  2016cited by this paper
• Meta‐analysis of clinical metabolic profiling studies in cancer: challenges and opportunities

  2016cited by this paper
• Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma

  2016cited by this paper
• Targeting Tumor Mitochondrial Metabolism Overcomes Resistance to Antiangiogenics.

  2016cited by this paper
• Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle-Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer.

  2016cited by this paper
• CRLX101 nanoparticles localize in human tumors and not in adjacent, nonneoplastic tissue after intravenous dosing

  2016cited by this paper
• Vessel co‐option is common in human lung metastases and mediates resistance to anti‐angiogenic therapy in preclinical lung metastasis models

  2016cited by this paper
• Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial.

  2016cited by this paper
• 2ME2 inhibits the activated hypoxia-inducible pathways by cabozantinib and enhances its efficacy against medullary thyroid carcinoma

  2015cited by this paper
• Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.

  2015cited by this paper
• Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity.

  2015cited by this paper
• 89Zr-Bevacizumab PET Visualizes Heterogeneous Tracer Accumulation in Tumor Lesions of Renal Cell Carcinoma Patients and Differential Effects of Antiangiogenic Treatment

  2015cited by this paper
• Pharmacodynamics and pharmacokinetics of oral topotecan in patients with advanced solid tumours and impaired renal function.

  2015cited by this paper
• CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer

  2015cited by this paper
• Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer

  2015cited by this paper
• Combined Effects of Pericytes in the Tumor Microenvironment

  2015cited by this paper
• Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib

  2015cited by this paper
• Hypoxia: a key player in antitumor immune response. A Review in the Theme: Cellular Responses to Hypoxia.

  2015cited by this paper
• PLGA/poloxamer nanoparticles loaded with EPAS1 siRNA for the treatment of pancreatic cancer in vitro and in vivo.

  2015cited by this paper
• Intrinsic bevacizumab resistance is associated with prolonged activation of autocrine VEGF signaling and hypoxia tolerance in colorectal cancer cells and can be overcome by nintedanib, a small molecule angiokinase inhibitor

  2014cited by this paper
• Pharmacodynamic and pharmacogenomic study of the nanoparticle conjugate of camptothecin CRLX101 for the treatment of cancer.

  2014cited by this paper
• Monitoring hypoxia and vasculature during bevacizumab treatment in a murine colorectal cancer model.

  2014cited by this paper
• Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia.

  2014cited by this paper
• 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.

  2014cited by this paper
• Endothelial cell metabolism: parallels and divergences with cancer cell metabolism

  2014cited by this paper
• Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: A phase I trial of bortezomib plus bevacizumab

  2014cited by this paper
• Weekly EZN-2208 (PEGylated SN-38) in combination with bevacizumab in patients with refractory solid tumors

  2014cited by this paper
• Translational Impact of Nanoparticle–Drug Conjugate CRLX101 with or without Bevacizumab in Advanced Ovarian Cancer

  2014cited by this paper
• Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors

  2014cited by this paper
• Hypoxia‐inducible factors in regulation of immune responses in tumour microenvironment

  2014cited by this paper
• Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle

  2013cited by this paper
• A systematic review on topoisomerase 1 inhibition in the treatment of metastatic breast cancer

  2013cited by this paper
• Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake.

  2013cited by this paper
• Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance.

  2013cited by this paper
• Role of endothelial cell metabolism in vessel sprouting.

  2013cited by this paper
• HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations.

  2013cited by this paper
• Recent agents targeting HIF‐1α for cancer therapy

  2013cited by this paper
• Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer

  2013cited by this paper
• Topoisomerase Inhibitors in Metastatic Breast Cancer: Overview of Current Practice and Future Development

  2013cited by this paper
• Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers.

  2013cited by this paper
• The VHL/HIF axis in clear cell renal carcinoma.

  2013cited by this paper
• Bevacizumab reduces tumor targeting of antiepidermal growth factor and anti‐insulin‐like growth factor 1 receptor antibodies

  2013cited by this paper
• Benefits of vascular normalization are dose and time dependent--letter.

  2013cited by this paper
• Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1α and STAT-3

  2013cited by this paper
• Tumor cell vasculogenic mimicry: from controversy to therapeutic promise.

  2012cited by this paper
• Sorafenib Inhibits Hypoxia-Inducible Factor-1α Synthesis: Implications for Antiangiogenic Activity in Hepatocellular Carcinoma

  2012cited by this paper
• Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells

  2012cited by this paper
• Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia

  2012cited by this paper
• Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs.

  2012cited by this paper
• Endothelial HIF-2α regulates murine pathological angiogenesis and revascularization processes.

  2012cited by this paper
• Preclinical study of the cyclodextrin-polymer conjugate of camptothecin CRLX101 for the treatment of gastric cancer.

  2012cited by this paper
• Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia

  2012cited by this paper
• Overcoming evasive resistance from vascular endothelial growth factor a inhibition in sarcomas by genetic or pharmacologic targeting of hypoxia-inducible factor 1α

  2012cited by this paper
• Molecular evolution of the metazoan PHD-HIF oxygen-sensing system.

  2011cited by this paper
• Metabolic reprogramming by HIF-1 promotes the survival of bone marrow-derived angiogenic cells in ischemic tissue.

  2011cited by this paper
• Metronomic Oral Topotecan with Pazopanib Is an Active Antiangiogenic Regimen in Mouse Models of Aggressive Pediatric Solid Tumor

  2011cited by this paper
• Potent and sustained inhibition of HIF-1α and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects

  2011cited by this paper
• Multihistology, Target-Driven Pilot Trial of Oral Topotecan as an Inhibitor of Hypoxia-Inducible Factor-1α in Advanced Solid Tumors

  2011cited by this paper
• HIF-1-dependent Expression of Angiopoietin-like 4 and L1CAM Mediates Vascular Metastasis of Hypoxic Breast Cancer Cells to the Lungs

  2011cited by this paper
• Antiangiogenic therapy: impact on invasion, disease progression, and metastasis

  2011cited by this paper
• Targeting hypoxia in cancer therapy

  2011cited by this paper
• Molecular mechanisms and clinical applications of angiogenesis

  2011cited by this paper
• Hypoxia-inducible factor-1-dependent mechanisms of vascularization and vascular remodelling.

  2010cited by this paper
• Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

  2010cited by this paper
• Bridging the Gap between Cytotoxic and Biologic Therapy with Metronomic Topotecan and Pazopanib in Ovarian Cancer

  2010cited by this paper
• The tumor microenvironment in non-small-cell lung cancer.

  2010cited by this paper
• Multiple receptor tyrosine kinases regulate HIF-1α and HIF-2α in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors

  2010cited by this paper
• Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.

  2009cited by this paper
• Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells

  2009cited by this paper
• Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma

  2009cited by this paper
• Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition

  2009cited by this paper
• Regulation of angiogenesis by oxygen and metabolism.

  2009cited by this paper
• Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization

  2009cited by this paper
• Potent Preclinical Impact of Metronomic Low-Dose Oral Topotecan Combined with the Antiangiogenic Drug Pazopanib for the Treatment of Ovarian Cancer

  2009cited by this paper
• Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth

  2008cited by this paper
• Cell Type–Specific, Topoisomerase II–Dependent Inhibition of Hypoxia-Inducible Factor-1α Protein Accumulation by NSC 644221

  2007cited by this paper
• Inhibition of DNA topoisomerases I and II, and growth inhibition of breast cancer MCF-7 cells by ouabain, digoxin and proscillaridin A.

  2006cited by this paper
• Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia.

  2006cited by this paper
• Overview of tumor cell chemoresistance mechanisms.

  2005cited by this paper
• Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway.

  2002cited by this paper
• Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity.

  2000cited by this paper

• Lactylation in cancer: molecular mechanisms and advances in clinical study

  2026cites this paper
• Vascular abnormalization confers tumor resistance to antiangiogenic therapy via downregulating angiostatic factors.

  2026cites this paper
• REVIEW ON THE ROLE OF NANOPARTICLES IN OVERCOMING DRUG RESISTANCE IN CANCER: MECHANISTIC AND THERAPEUTIC PERSPECTIVES

  2025cites this paper
• Decoding the metastatic nexus: how chronic stress reprograms neuroendocrine-metabolic-microbiome circuits to fuel tumor metastasis.

  2025cites this paper
• The unique signature of tyrosine kinase inhibitor-induced hypothyroidism.

  2025cites this paper
• Nanoparticles for Cancer Immunotherapy: Innovations and Challenges

  2025cites this paper
• Lactate and lactylation in cancer

  2025cites this paper
• Endothelial cell in tumor angiogenesis: Origins, mechanisms, and therapeutic implication

  2025cites this paper
• Decoding tumor angiogenesis: pathways, mechanisms, and future directions in anti-cancer strategies

  2025cites this paper
• Exploring the Mechanisms of Epithelial-Mesenchymal Transition (EMT) in Breast Cancer: The Role of MicroRNA and the Therapeutic Promise of Bioactive Compounds from Edible Plants

  2025cites this paper
• Origins and molecular effects of hypoxia in cancer.

  2024cites this paper
• Artificial intelligence-based MRI radiomics and radiogenomics in glioma

  2024cites this paper
• Recent advances and future directions on small molecule VEGFR inhibitors in oncological conditions.

  2024cites this paper
• Hypoxia-inducible factor in breast cancer: role and target for breast cancer treatment

  2024cites this paper
• Biochemical hallmarks-targeting antineoplastic nanotherapeutics

  2024cites this paper
• Activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrence of glioblastoma

  2023cites this paper
• Nanodelivery systems: An efficient and target‐specific approach for drug‐resistant cancers

  2023cites this paper
• Tumor-derived lactate promotes resistance to bevacizumab treatment by facilitating autophagy enhancer protein RUBCNL expression through histone H3 lysine 18 lactylation (H3K18la) in colorectal cancer

  2023cites this paper
• Construction of subtype classifiers and validation of a prognostic risk model based on hypoxia-associated lncRNAs for lung adenocarcinoma

  2023cites this paper
• Angiogenic signaling pathways and anti-angiogenic therapy for cancer

  2023cites this paper
• Hypoxia promotes conversion to a stem cell phenotype in prostate cancer cells by activating HIF-1α/Notch1 signaling pathway

  2023cites this paper
• GATA6-AS1 suppresses epithelial–mesenchymal transition of pancreatic cancer under hypoxia through regulating SNAI1 mRNA stability

  2023cites this paper
• Hypoxia signaling and metastatic progression.

  2023cites this paper
• Atractylenolide III Attenuates Angiogenesis in Gastric Precancerous Lesions Through the Downregulation of Delta-Like Ligand 4

  2022cites this paper
• Destruction of tumor vasculature by vascular disrupting agents in overcoming the limitation of EPR effect.

  2022cites this paper
• Opportunities and Challenges of Nanoparticles in Digestive Tumours as Anti-Angiogenic Therapies

  2022cites this paper
• Efficacy of Polymer-Based Nanomedicine for the Treatment of Brain Cancer

  2022cites this paper
• Palliating the escalated post-PDT tumor hypoxia with a dual cascade oxygenation nanocomplex

  2022cites this paper
• Path analysis of intra-metastatic hypoxia in breast cancer

  2022cites this paper
• Targeting hypoxia-inducible factors for breast cancer therapy: A narrative review

  2022cites this paper
• Identification and validation of a hypoxia-immune signature for overall survival prediction in lung adenocarcinoma

  2022cites this paper
• Construction of a Six-Gene Prognostic Risk Model Related to Hypoxia and Angiogenesis for Cervical Cancer

  2022cites this paper
• Hypoxic signaling in lymphatic colorectal cancer metastasis

  2022cites this paper
• Tumor-Derived Lactate Creates a Favorable Niche for Tumor via Supplying Energy Source for Tumor and Modulating the Tumor Microenvironment

  2022cites this paper
• Co-delivery of photosensitizer and diclofenac through sequentially responsive bilirubin nanocarriers for combating hypoxic tumors

  2021cites this paper
• A Novel Prognostic and Predictive Signature for Lung Adenocarcinoma Derived from Combined Hypoxia and Infiltrating Immune Cell-Related Genes in TCGA Patients

  2021cites this paper
• PESV represses non-small cell lung cancer cell malignancy through circ_0016760 under hypoxia

  2021cites this paper
• Chronic Stress: Impacts on Tumor Microenvironment and Implications for Anti-Cancer Treatments

  2021cites this paper
• ADAM17 Mediates Hypoxia-Induced Keratinocyte Migration via the p38/MAPK Pathway

  2021cites this paper
• Modulating hypoxia inducible factor-1 by nanomaterials for effective cancer therapy.

  2021cites this paper
• Cardiotoxicity of antiangiogenic drugs: causes and mechanisms

  2021cites this paper
• Tumor vessel co-option probed by single-cell analysis.

  2021cites this paper
• The role of anlotinib-mediated EGFR blockade in a positive feedback loop of CXCL11-EGF-EGFR signalling in anaplastic thyroid cancer angiogenesis

  2021cites this paper
• Improved understanding of gastrointestinal stromal tumors biology as a step for developing new diagnostic and therapeutic schemes.

  2021cites this paper
• Synthesis and Antitumor Application of Antiangiogenetic Gold Nanoclusters.

  2021cites this paper
• Prognostic and Predictive Value of a 15 Transcription Factors (TFs) Panel for Hepatocellular Carcinoma

  2020cites this paper
• DHPAC, a novel microtubule depolymerizing agent, suppresses angiogenesis and vasculogenic mimicry formation of human non‐small cell lung cancer

  2020cites this paper
• Revision of the Regioselectivity of the Beirut Reaction of Monosubstituted Benzofuroxans with Benzoylacetonitrile. 6-Substituted quinoxaline-2-carbonitrile 1,4- dioxides: Structural Characterization and Estimation of Anticancer Activity and Hypoxia Selectivity.

  2020cites this paper
• Hypoxia compensates cell cycle arrest with progenitor differentiation during angiogenesis

  2020cites this paper
• Inhibitors of Hypoxia-Inducible Factors as Treatment for Cancer.

  2020cites this paper
• Application of nanotechnology for enhancing photodynamic therapy via ameliorating, neglecting, or exploiting tumor hypoxia

  2020cites this paper
• Light-enhanced hypoxia-responsive and azobenzene cleavage-triggered size-shrinkable micelles for synergistic photodynamic therapy and chemotherapy.

  2020cites this paper
• Current developments in nanotechnology for improved cancer treatment, focusing on tumor hypoxia.

  2020cites this paper
• Hypoxia: Turning vessels into vassals of cancer immunotolerance.

  2020cites this paper
• Up-regulation of hypoxia-inducible factor antisense as a novel approach to treat ovarian cancer

  2020cites this paper
• Targeting the Redox Landscape in Cancer Therapy

  2020cites this paper
• Development and validation of a hypoxia-related gene signature to predict overall survival in early-stage lung adenocarcinoma patients

  2020cites this paper
• Metronomic chemotherapy offsets HIFα induction upon maximum‐tolerated dose in metastatic cancers

  2020influential citation
• Hypoxia‐inhibited miR‐338‐3p suppresses breast cancer progression by directly targeting ZEB2

  2020cites this paper
• Reshaping Tumor Blood Vessels to Enhance Drug Penetration with Multi-strategy Synergistic Nanosystem.

  2020cites this paper
• Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance

  2020cites this paper
• Metabolic rewiring in the promotion of cancer metastasis: mechanisms and therapeutic implications

  2020cites this paper
• DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives

  2020cites this paper
• Attenuating hypoxia driven malignant behavior in glioblastoma with a novel hypoxia-inducible factor 2 alpha inhibitor

  2020cites this paper
• Hypoxia increases the apoptotic response to betulinic acid and betulin in human non-small cell lung cancer cells.

  2020cites this paper
• Anti-Angiogenic Therapy in the Treatment of Non-Small Cell Lung Cancer

  2020cites this paper
• Heparanase and the hallmarks of cancer

  2020cites this paper
• Biophysical and Epigenetic Regulation of Cancer Stemness, Invasiveness, and Immune Action

  2020cites this paper
• Development and validation of a hypoxia-related gene pair signature to predict overall survival in head and neck squamous cell carcinoma

  2020cites this paper
• Hypoxia-activated probe for NIR fluorescence and photoacoustic dual-mode tumor imaging

  2020cites this paper
• Prognostic and Predictive Value of a 15 Transcription Factors (TFs) Panel for Hepatocellular Carcinoma

  2020cites this paper
• Hypoxia in the Initiation and Progression of Neuroblastoma Tumours

  2019cites this paper
• Matrine Reverses the Warburg Effect and Suppresses Colon Cancer Cell Growth via Negatively Regulating HIF-1α

  2019cites this paper
• Hybrid manganese dioxide-bovine serum albumin nanostructure incorporated with doxorubicin and IR780 for enhanced breast cancer chemo-photothermal therapy

  2019cites this paper
• Explorer miR-15 a /-16 Inhibit Angiogenesis by Targeting the Tie 2 Coding Sequence : Therapeutic Potential of a miR-15 a / 16 Decoy System in Limb Ischemia

  2019cites this paper
• Hypoxic exosomes facilitate angiogenesis and metastasis in esophageal squamous cell carcinoma through altering the phenotype and transcriptome of endothelial cells

  2019cites this paper
• Hypoxia-Dependent Angiogenesis and Lymphangiogenesis in Cancer.

  2019cites this paper
• miR-15a/-16 Inhibit Angiogenesis by Targeting the Tie2 Coding Sequence: Therapeutic Potential of a miR-15a/16 Decoy System in Limb Ischemia

  2019cites this paper
• Discovery of chalcone-modified estradiol analogs as antitumour agents that Inhibit tumour angiogenesis and epithelial to mesenchymal transition.

  2019cites this paper
• Bortezomib and metformin opposingly regulate the expression of hypoxia-inducible factor alpha and the consequent development of chemotherapy-induced painful peripheral neuropathy

  2019cites this paper
• Innervation of cervical carcinoma is mediated by cancer-derived exosomes.

  2019cites this paper
• Rationale for Combining Radiotherapy and Immune Checkpoint Inhibition for Patients With Hypoxic Tumors

  2019cites this paper
• Impairment of hypoxia-induced angiogenesis by LDL involves a HIF-centered signaling network linking inflammatory TNFα and angiogenic VEGF

  2019cites this paper
• Hypoxia‐sensitive LINC01436 is regulated by E2F6 and acts as an oncogene by targeting miR‐30a‐3p in non‐small cell lung cancer

  2019cites this paper
• Lactate: A Metabolic Driver in the Tumour Landscape.

  2019cites this paper
• Effects of Enoxaparin Emulsion on Dimethylbenzanthracene-induced Breast Cancer in Female Rats

  2018cites this paper
• The Current Landscape of 3D In Vitro Tumor Models: What Cancer Hallmarks Are Accessible for Drug Discovery?

  2018cites this paper
• HIF-1α-derived cell-penetrating peptides inhibit ERK-dependent activation of HIF-1 and trigger apoptosis of cancer cells under hypoxia

  2018cites this paper
• Redundant angiogenic signaling and tumor drug resistance.

  2018cites this paper
• Effects of curcumin on hypoxia‐inducible factor as a new therapeutic target

  2018cites this paper
• Advanced nanomaterials targeting hypoxia to enhance radiotherapy

  2018cites this paper
• Weipixiao attenuate early angiogenesis in rats with gastric precancerous lesions

  2018cites this paper
• Bridging angiogenesis and immune evasion in the hypoxic tumor microenvironment.

  2018cites this paper
• The role of hypoxic signalling in metastasis: towards translating knowledge of basic biology into novel anti-tumour strategies

  2018cites this paper
• Hypoxia-inducible factor 2α: a novel target in gliomas.

  2018cites this paper
• New strategies in achieving antiangiogenic effect: Multiplex inhibitors suppressing compensatory activations of RTKs

  2018cites this paper
• Hypoxic pathobiology of breast cancer metastasis.

  2017cites this paper
• Targeted Therapy for Medullary Thyroid Cancer: A Review

  2017cites this paper
• G Protein-Coupled Receptors at the Crossroad between Physiologic and Pathologic Angiogenesis: Old Paradigms and Emerging Concepts

  2017cites this paper